Immatics Biotechnologies Gmbh Stock Cash Per Share
| IMTXW Stock | USD 0.30 0.04 11.76% |
immatics biotechnologies GmbH fundamentals help investors to digest information that contributes to Immatics Biotechnologies' financial success or failures. It also enables traders to predict the movement of Immatics Stock. The fundamental analysis module provides a way to measure Immatics Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immatics Biotechnologies stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 5.29 | 2.74 |
Immatics | Cash Per Share |
immatics biotechnologies GmbH Company Cash Per Share Analysis
Immatics Biotechnologies' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Immatics Biotechnologies Cash Per Share | 2.74 |
Most of Immatics Biotechnologies' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, immatics biotechnologies GmbH is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immatics Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Immatics Biotechnologies is extremely important. It helps to project a fair market value of Immatics Stock properly, considering its historical fundamentals such as Cash Per Share. Since Immatics Biotechnologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immatics Biotechnologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immatics Biotechnologies' interrelated accounts and indicators.
Click cells to compare fundamentals
Immatics Cash Per Share Historical Pattern
Today, most investors in Immatics Biotechnologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immatics Biotechnologies' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immatics Biotechnologies cash per share as a starting point in their analysis.
Immatics Biotechnologies Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Immatics Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Immatics Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immatics Biotechnologies' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immatics Biotechnologies could also be used in its relative valuation, which is a method of valuing Immatics Biotechnologies by comparing valuation metrics of similar companies.Immatics Biotechnologies is currently under evaluation in cash per share category among its peers.
Immatics Biotechnologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immatics Biotechnologies from analyzing Immatics Biotechnologies' financial statements. These drivers represent accounts that assess Immatics Biotechnologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immatics Biotechnologies' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 583.4M | 423.8M | 743.6M | 546.8M | 767.3M | 480.3M | |
| Enterprise Value | 483.3M | 222.4M | 620.4M | 412.8M | 564.3M | 373.5M |
Immatics Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.42) % | ||||
| Number Of Shares Shorted | 714 | ||||
| Revenue | 54 M | ||||
| EBITDA | (88.93 M) | ||||
| Net Income | (96.99 M) | ||||
| Total Debt | 15.4 M | ||||
| Book Value Per Share | 2.66 X | ||||
| Cash Flow From Operations | 18.23 M | ||||
| Number Of Employees | 542 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 673 M | ||||
| Total Asset | 509.96 M | ||||
| Retained Earnings | (597.29 M) | ||||
| Working Capital | 292.82 M | ||||
| Net Asset | 509.96 M |
About Immatics Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze immatics biotechnologies GmbH's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immatics Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of immatics biotechnologies GmbH based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.